Opinion|Videos|February 4, 2025

Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies

Experts discuss the evolving landscape of chemotherapy and immunotherapy options for patients with non-muscle invasive bladder cancer (NMIBC).

Episodes in this series

EP. 1 A Comprehensive Overview of NMIBC

EP. 1 A Comprehensive Overview of NMIBC

EP. 2 Standard of Care: Staging Considerations and Establishing Patient-Provider Relationships

EP. 2 Standard of Care: Staging Considerations and Establishing Patient-Provider Relationships

EP. 3 Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies

EP. 3 Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies

EP. 4 New Horizons in NMIBC: Pipeline Innovations and Clinical Perspectives

EP. 4 New Horizons in NMIBC: Pipeline Innovations and Clinical Perspectives

EP. 5 Reducing Recurrence in NMIBC and Novel Treatment Approaches on the Horizon

EP. 5 Reducing Recurrence in NMIBC and Novel Treatment Approaches on the Horizon

EP. 6 Practical Patient-Centered Logistics: Providing Care to Patients With NMIBC

EP. 6 Practical Patient-Centered Logistics: Providing Care to Patients With NMIBC

EP. 7 The Mental Health Impact of NMIBC Treatment: Management With Your Patient

EP. 7 The Mental Health Impact of NMIBC Treatment: Management With Your Patient

EP. 8 Navigating The Future of NMIBC Trails: Key Insights and Takeaways

EP. 8 Navigating The Future of NMIBC Trails: Key Insights and Takeaways

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Referral Pathways and Unmet Needs in Perioperative MIBC Care

ByJoshua J. Meeks, MD, PhD

September 4th 2026

MIBC Treatment Timeline and Skin Toxicity: What Urologists Should Know

ByJoshua J. Meeks, MD, PhD

September 4th 2026

What the Efficacy Data from KEYNOTE-B15/EV-304 Revealed

ByJoshua J. Meeks, MD, PhD

September 4th 2026

FDA Expands MIBC Approval: What Changed for Platinum-Eligible Patients

ByJoshua J. Meeks, MD, PhD

September 4th 2026

Rectal Spacer Evidence: Acute Toxicity, Durability, and Safety

ByAurelie Garant, MD,Daniel Welchons, MD

September 4th 2026

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

AI-generated profiles impersonate female urologists to market ED products online

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

Doublet or triplet? Urologists weighs in on mCSPC options

John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC

Alternative BCG strains may help address ongoing supply challenges in NMIBC